59 results about "Allergy disorders" patented technology

The invention provides a compound betamethasone suspension injection, which is a compound preparation composed of low-solubility betamethasone dipropionate and high-solubility betamethasone sodium phosphate. Long-lasting, it can be used for the treatment of musculoskeletal and cartilage tissue diseases, allergic diseases, skin diseases, collagen diseases, tumors and other clinical diseases.

A functional food composition for treating allergy, comprising Saururus chinensis, Plantago asiatica, Poncirus trifoliata and Schisandra chinensis extracts, as active ingredients, a tea composition comprising the same and a manufacturing method thereof. The functional food and tea compositions for treatment of allergy in accordance with the present invention are therapeutically effective for any type of allergic diseases, irrespective of allergic causes. In particular, the tea composition advantageously enables easy and regular administration at need, which can achieve anti-allergic effects without particular efforts for treatment of diseases.

The invention discloses an application of a DGK alpha (diacylglycerol kinase alpha) gene-chitosan nanoparticle as a unique active component in preparing a medicine for treating allergic asthma as well as a preparation method of the DGK alpha gene-chitosan nanoparticle. The invention, aiming at shortcomings that naked DGK alpha plasmid is easy to be damaged by nuclease, acid, alkali and the like in the body, prepares the DGK alpha gene-chitosan nanoparticle through chitosan, so as to effectively protect the DGK alpha plasmid, enhance the activity of the DGK alpha plasmid in the body and promote the DGK alpha gene to develop better function in the body. The DGK alpha, based on a function of induction of T cell anergy, can induce immune tolerance. The DGK alpha gene-chitosan nanoparticle prepared by the invention can inhibit egg albumin-induced airway inflammation of asthmatic mice, reduce serum egg albumin specific IgE level, and is expected to be used for treating asthma and other allergic diseases.

The invention discloses application of a carbon-21 steride compound STA (stephanthraniline A) in preparation of anti-inflammatory medicines and immunosuppressive agents. The immunosuppressive agents comprise medicines for preventing and treating rejection in organ transplantation, medicines for preventing and treating allergic diseases or medicines for preventing and treating autoimmune diseases. The results of a variety of in-vivo and in-vitro experiments demonstrate that the compound has the effect of T lymphocyte activation suppression and is different from the traditional steride anti-inflammatory medicines in the action mechanism, i.e. the STA acts without virtue of a glucocorticoid receptor.

The invention discloses a pseudolaric acid B and the application of derivative thereof in the preparation of immunity inhibitor. Experiments prove that the pseudolaric acid B and the derivative thereof have excellent immunity inhibiting effect and lower toxicity, so that the pseudolaric acid B and the derivative thereof or pseudolaric acetate and salt of the derivative of the pseudolaric acid B can be taken as medicine for preventing or treating exclusive reaction, autoimmune disease, inflammatory disease, allergic disease and the like which are related to immunity and caused by organ or skin grafting of mammal (especially human beings).

The invention relates to traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition for treating rhinitis. Rhinitis is an abnormal allergic disease happening in nasal cavity mucosal, is a normal disease in otolaryngology, can trigger a plurality of complications, wherein the most common complication is bronchial asthma, and sometimes the complications comprise nasosinusitis, tympanitis, allergic sphagitis, and the like. The traditional Chinese medicine composition for treating rhinitis is composed of the following medicinal materials by weight: 5 to 10 grams of radix bupleuri, 5 to 12 grams of cocklebur fruit, 8 to 15 grams of radix scrophulariae, 2 to 5 grams of asarum herb, 8 to 12 grams of Chinese yam, 2 to 5 grams of licorice, 5 to 15 grams of dwarf lilyturf tuber, 5 to 15 grams of dried radix rehmanniae, 5 to 15 grams of white peony root, 8 to 12 grams of prepared rehmanniae radix, 8 to 12 grams of poria cocos, 5 to 10 grams of lily magnolia, 5 to 12 grams of anemarrhena, 8 to 12 grams of oroxylum indicum vent, 5 to 15 grams of radix scutellariae, 8 to 12 grams of loquat leaf, 8 to 15 grams of dendrobium, 5 to 15 grams of Chinese angelica, 5 to 15 grams of peach seed, and 8 to 12 grams of safflower. The traditional Chinese medicine has a prominent effect on treating allergic rhinitis, also has a prominent effect on rhinitis and nasal mucosa inflammation caused by wind-heat, has the advantages of short treatment period, prominent effect, user-friendliness, safety, and no side effect, can prevent rhinitis through regular using of the composition, and is capable of treating both the symptoms and the roots.

The invention relates to a levocetirizine hydrochloride chewable tablet for relieving hypersensitivity caused by allergy diseases and the preparation technology thereof. Levocetirizine hydrochloride has stronger bitterness, in the invention, by adopting the composite of Beta-cyclodextrin and microcrystalline cellulose, the medicine is prepared to be inclusion compound so as to cover up the bitterness of the medicine, the prepared medicine is better in mouth-feel and is convenient to take, the process operability in preparing the inclusion compound and the stability of the levocetirizine hydrochloride chewable tablet are enhanced at the same time, the levocetirizine hydrochloride chewable tablet is particularly suitable for old and child patients having difficulty in swallowing, enhances the compliance of the patients and has a better marketable value.

The invention relates to novel application of a pharmaceutical composition to preparing medicament for preventing and treating allergic diseases. The prescription consists of 66 portions of astragalus, 27 portions of red paeonia, 27 portions of Salviae miltiorrhiza radix, 27 portions of angelica, 27 portions of Szechuan lovage rhizome, 27 portions of peach kernel, 13 portions of safflower, 13 portions of prepared libanotus, 13 portions of prepared myrrh, 20 portions of caulis milletiae, 27 portions of achyranthis root, 20 portions of cassia twig, 27 portions of mulberry twig, 27 portions of earthworm, 13 portions of scorpion, and 27 portions of leech. Medicament forms comprise pill, granule, hard capsule, soft capsule, troche, dripping pill or oral liquid. The invention aims to provide novel treatment application of the pharmaceutical composition, which enlarges the clinical application range, and avoids waste of favorable medicament resource.

The invention discloses a detection device, comprising a detection plate and a detection plate box, wherein the detection plate is arranged in the detection plate box, the detection plate comprises a plurality of inspection holes and passages, the depth of the inspection holes is larger than that of the passages, and the detection holes are communicated through the passages. The detection plate adopts materials capable of coating food immunogen and is provided with a mark symbol. The detection device provided by the invention is used for detecting whether human body is diseased because of food intolerances and for detecting reaction of immune tolerance reaction of human body to various foods. The detection method is simple and convenient, the detection result is accurate and reliable, various allergic diseases to human body caused by food intolerances are avoided, and the mark symbol can avoid mistaking corresponding to-be-detected sample in detection. The detection device has the advantages of low cost, and being suitable for mass production.

The invention discloses an application of MBL in preparing a drug for preventing or treating disease taking Tregs as a target spot and belongs to the technical field of a novel application of mannan binding lectin. The key point of the technical scheme is as follows: the invention relates to the application of MBL in preparing a drug for preventing or treating infectious diseases, autoimmune diseases or / and allergic diseases induced by taking Tregs as the target spot, wherein MBL realizes functions of the drug by accelerating induced differentiation of a CD4<+>CD25-T cell toward a Tregs cell. Through exploration, a novel factor of adjusting induced differentiation of the Tregs cell is obtained, that is, MBL directly enhances induced differentiation of the CD4<+>CD25-T cell toward the Tregs cell. The application disclosed by the invention highlights a novel function of MBL, and MBL not only plays an important anti-infection role in inherent immunity, but also can be a pertinent target spot for treating various autoimmune diseases and inflammatory diseases in intervention of induced differentiation of the Tregs cell.

The invention relates to novel application of a pharmaceutical composition to preparing a medicine for preventing and treating allergic diseases. The prescription consists of the following materials: 300 portions of radix codonopsis pilosulae, 400 portions of rhizoma polygonati, 60 portions of radix notoginseng, 40 portions of amber, and 200 portions of nard, and the formulation includes pill, granule, hard capsule, soft capsule, tablet, dripping pill or oral taking liquid. The aim of the invention is to provide novel treatment application of the pharmaceutical composition, which widens the clinical application range of the invention, and avoids waste of good medicine resources.

The invention discloses a platanus pollen allergen Pla a 3, a monoclonal antibody thereof and a preparation method of the monoclonal antibody. The platanus pollen allergen Pla a 3 is separated from phoenix tree pollen in a purification mode, and the apparent molecular weight of fusion protein SUMO-Pla a 3 of the platanus pollen allergen Pla a 3 is measured as 28 kDa through SDS-PAGE. The protein Pla a 3 is separated from the phoenix tree pollen in the purification mode, the molecular weight of the fusion protein SUMO-Pla a 3 of the platanus pollen allergen Pla a 3 is measured as 28 kDa through SDS-PAGE. The monoclonal antibody prepared through the platanus pollen allergen Pla a 3 is characterized in that the monoclonal antibody can be specifically combined with the platanus pollen allergen Pla a 3 and plays an important role in diagnosis and treatment of allergic skin diseases, asthmas and other I-type allergic diseases caused by phoenix tree pollen.

Alpha-glycosylceramide compounds capable of activating NKT cells and compositions thereof are disclosed. Methods for activating NKT cells, methods of stimulating an immune response in a subject, and methods of treating cancer, infectious diseases, autoimmune diseases and disorders, or allergy diseases or disorders with the compounds and compositions are also disclosed.

The invention discloses an application of MBL in preparing a drug for preventing or treating disease induced by an effector T cell and belongs to the technical field of a novel application of mannan binding lectin. The key point of the technical scheme is as follows: the invention relates to the application of MBL in preparing a drug for preventing or treating infectious diseases, autoimmune diseases or / and allergic diseases induced by the effector T cell, wherein MBL realizes functions of the drug by enhancing iTreg cell and inhibiting proliferation of the effector T cell. Through researches, a novel factor of adjusting the inhibition function of the Tregs cell is obtained, that is, MBL directly enhances the inhibition action of the Tregs cell on proliferation of the effector T cell. The application disclosed by the invention highlights a novel function of MBL, and MBL not only plays an important anti-infection role in inherent immunity, but also can be a pertinent target spot for treating various autoimmune diseases and inflammatory diseases in intervention of the function of the Tregs cell.

The invention provides a drug composition containing rosuvastatin calcium and a preparation method and application thereof, and belongs to the field of drugs. The drug composition is prepared from therosuvastatin calcium, lactose, microcrystalline cellulose, tricalcium phosphate, magnesium stearate and polyvinylpolypyrrolidone. The preparation method of the drug composition comprises the steps: in parts by weight, the microcrystalline cellulose, the lactose, the tricalcium phosphate and part of the polyvinylpolypyrrolidone are mixed, wet granulation is conducted, after drying, granulation isconducted through a screen of 20-40 meshes, and blank particles are obtained; and then the blank particles are mixed with the rosuvastatin calcium, the remaining polyvinylpolypyrrolidone and the magnesium stearate for preparation. The drug composition is reasonable in component, and through research, the inventor finds that the drug composition is excellent in curative effect on an I-type allergicdisease, can be used for preparing drugs for preventing or treating the I-type allergic disease, and is wide in application prospect.

The invention discloses a preparation method of diacylglycerol kinase alpha gene-chitosan nanoparticles. The preparation method is characterized in that specific to the disadvantages that naked DGK alpha plasmids are easy to destroy by nucleases, acids, bases and the like in bodies, and the DGK alpha gene-chitosan nanoparticles are prepared by using chitosan and are capable of effectively protecting the DGK alpha plasmids, enhancing the activity of the DGK alpha plasmids in the bodies and promoting a DGK alpha gene to work in the bodies relatively well. The DGK alpha has the effect of inducing T-cell anergy and can induce immune tolerance. The DGK alpha gene-chitosan nanoparticles prepared by the method can inhibit airway inflammation of asthma rats induced by egg albumin and reduce the specific IgE (immunoglobulin E) level of serum egg albumin and is expected to be applied to treatment of allergic diseases such as asthma.

The invention provides an application of a urine keratin, type II cytoskeletal 1 (Keratin, type II cytoskeletal 1) protein and a polypeptide fragment thereof, and particularly relates to an application of the urine keratin, type II cytoskeletal 1 and the polypeptide fragment thereof in preparation of a preparation for detecting allergic diseases. The allergic diseases are also known as allergic diseases, and the typical allergic diseases (allergic diseases) comprise allergic rhinitis, bronchial asthma, allergic dermatitis, eczema, allergic conjunctivitis, allergic shock and the like, and are collectively known as allergic diseases below. Researches prove that compared with a healthy human group (normal control), the expression of the urine keratin, II type cytoskeleton 1 and the polypeptide fragment thereof in an allergic disease patient group is improved, and the urine keratin, II type cytoskeleton 1 and the polypeptide fragment thereof can be used for auxiliary diagnosis of allergic disease patients. The advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of the urine sample are exerted, and the urine keratin, II-type cytoskeleton 1 and the polypeptide fragments thereof are detected by utilizing the urine sample.

The invention discloses a traditional Chinese medicine external lotion for treating anal eczema. The anal eczema is an allergic disease, and the traditional Chinese medicine believes that the anal eczema is caused by visceral dysfunction, dysfunction of the spleen in transport, interior dampness-heat, further contraction of external evil, fighting of three evils, namely wind, damp and heat, obstruction of qi-blood circulation, and skin invasion. The traditional Chinese medicine external lotion is prepared from the selected traditional Chinese medicines including saussurea nigrescens, salix hypoleuca, cycas revoluta, lindernia anagallis, bulleyia yunnanensis, root of cinnamomum burmannii, hyptis suaveloens, abrus cantoniensis hance, sedum lineare and folium mori; clinical experiments show that the total effective rate of the traditional Chinese medicine composition reaches 96% which is obviously superior to the total effective rate being 70% of a control group, and the curative effect is excellent.

The invention aims to provide a traditional Chinese medicine external washing agent for treating chronic perianal eczema. Chronic perianal eczema is a common allergic disease, and main clinical presentations of chronic perianal eczema are severe local skin itching, skin lesion surface roughness, hypertrophy, lichenification, depigmentation and anal skin fissure. The traditional Chinese medicine external washing agent is prepared by selecting the following traditional Chinese medicines: engler abelia, spreading hedyotis herb, thymifoious euphorbia herb, herb of fortune silene, commen bomhax flower, root or bark of gluey litse, all-grass of siam falsenettle, herb of twinflower groundsel, stem of littleleaf rourea and purpleflower holly leaf. By virtue of clinical tests, the traditional Chinese medicine external washing agent provided by the invention has the total effective rate of 90.0%, and is significant in curative effects.

The present invention relates to a combined bacterial vaccine for curing allergic diseases of allergic rhinitis, allergic conjunctivitis, various bronchitis and asthma and deafness resulted from medicine with good therapeutic effect. Said combined bacterial vaccine is formed from diplococcus pneumoniae, alpha-hemolytic streptococcus, beta-hemolytic streptococcus, staphylococuus aureus, staphylococcus epidermidis and others.

The invention provides a detection membrane strip, a detection card and a detection kit for allergen detection, which can be used for rapidly detecting whether a human body has lesion or immune tolerance reaction due to food, pollen, dust mites, mould and the like, the detection method is simple, convenient and rapid, and the detection result is accurate and reliable. Various allergic diseases caused by allergens to human bodies are avoided, different detection requirements are met, the cost is low, the structure is simple, assembly is easy, and the detection membrane strip, the detection card and the detection kit are suitable for large-scale production, can be suitable for whole blood detection, and are particularly suitable for self-inspection of infants and family members; the invention provides an immunofiltration device capable of limiting flow, and aims to enable liquid to only permeate through a target position, slow down the flow speed and improve the detection sensitivity. A formula of the sample diluent is provided, so that the treatment of a whole blood sample is facilitated, and the test is smoothly carried out; the invention provides the whole blood filter membrane, which is beneficial to filtering large-particle substances in a sample when detecting that the sample is whole blood, and is convenient for the sample to smoothly pass through the nitrocellulose membrane.

The present invention relates to a combined bacterial vaccine for curing allergic diseases of allergic rhinitis, allergic conjunctivitis, various bronchitis and asthma and deafness resulted from medicine with good therapeutic effect. Said combined bacterial vaccine is formed from diplococcus pneumoniae, alpha-hemolytic streptococcus, beta-hemolytic streptococcus, staphylococuus aureus, staphylococcus epidermidis and others.

Rheumatism is an allergic disease related to group A streptococcus, involves connective tissues of a whole body, is represented as acute or chronic connective tissue inflammation, mainly degeneration and necrosis of collagen fibers. Rheumatism mostly involves heart and joints, and secondly subcutaneous, serosa, blood vessels and brain, and is called rheumatic fever in the acute phase. The invention relates to a medicinal liquor composition for dispelling wind and activating collaterals. The medicinal liquor composition is prepared from the following components: 50-150g of garter snake, 10-50g of ligusticum wallichii, 10-50g of Sichuan papaya, 10-50g of incised notopterygium, 10-50g of radix angelicae pubescentis, 10-50g of obscured homalomena rhizome, 10-30g of radix aconiti preparata, 10-50g of gentiana macrophylla, 20-60g of radix cyathulae, 30-80g of pterospermum heterophyllum and 50-150g of rock candy.

A biomarker is provided for an allergic disease caused by an allergic reaction that is caused not exclusively by histamine release, such as pruritus, and use of the same. Use of Granzyme A as a biomarker makes it possible to provide an indication for chronic itching skin disease, for which existing antiallergic drugs have little effect, and easily and adequately allow diagnosis of the disease. It is possible to, for example, make a diagnosis of an allergic disease with an IV type allergy-like reaction not depending on the antigen-antibody reaction system. Screening with the use of Granzyme A enables the development of novel remedies for allergic diseases. Moreover, a drug capable of specifically controlling the action of a granzyme enables treatment of allergic disease with little side effect.

A 3-glycosylflavone or its derivatives, their preparing process, and their application in preparing the medicines for treating immune diseases, such as autoimmunity disease or allergic disease, are disclosed.

The invention discloses an indoor botanical miticide as well as a use method and application thereof. The miticide comprises the following components in parts by weight: 2-4.5 parts of motherwort extract, 1-2 parts of white paeony root extract, and 1-2 parts of paeony root extract, with the balance being deionized water. The miticide belongs to a pure natural plant extract, has no harm to human bodies and other organisms, has no residue after being used, and can be widely used for killing dust mites in different indoor environments. Dust mite allergens are main allergens causing allergic reaction diseases, about 80%-100% of asthma patients are allergic to dust mites, and the use of the miticide can effectively control the density of indoor dust mites, so that the allergens related to indoor dust mites are reduced, the occurrence of dust mite allergic diseases is favorably prevented, and effective help is provided for clinical treatment of dust mite allergic diseases.

The invention discloses a new medical application of rhodospirillum, namely the application of rhodospirillum in preparing a medicine for treating and preventing allergic diseases of types I, II, III and IV, which is mainly used for diminishing inflammation, clearing heat and relieving pain. No medicine with a real treatment effect on the hypersensitive allergic diseases is available except glucocorticoid and immunosuppressor. A great quantity of animal experiments prove that the rhodospirillum preparation is safe and effective; the rhodospirillum preparation is clinically used for preventing and treating the allergic diseases of types I, II, III and IV such as eczema, urticaria, allergic asthma, diabetes, hyperthyroidism, uremia, lupus erythematosus, psoriasis, various ulcers, burns and scales, various cancers and the like, and also can be used for preventing and treating the cardiovascular diseases such as arteriosclerosis, hypertension and the like; and a great quantity of clinical cases indicate that the effective rate of the rhodospirillum preparation in treating allergic diseases is 100%; the rehabilitation degree depends on the constitution and condition of patients; and younger patients enjoy a better long-term effect.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The present application describes modulators of chemokine receptor activity of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.